Table 1 Vaccination-related input variables
From: Cost-effectiveness of human papillomavirus vaccination in Germany
Parameter | Value | Source | |
|---|---|---|---|
Vaccine efficacy | HPV 16/18 in females | 98% | |
HPV 6/11 in females (quadrivalent vaccine only) | 100% | [83] | |
HPV 16/18 in males | 90.4% | [84] | |
HPV 6/11 in males (quadrivalent vaccine only) | 90.4% | [84] | |
Cross-protection provided by the quadrivalent vaccine (considered in sensitivity analysis only) | HPV 31/33/35/39/45/51/52/56/58/59 | 32.5% | |
Cross-protection provided by the bivalent vaccine (considered in sensitivity analysis only) | HPV 31/33/35/39/45/51/52/56/58/59 | 68.4% | [86] |
Duration of full protection | 10Â years | Assumption | |
Waning (after the duration of full protection) | 0.1 per year | Assumption | |
Vaccination coverage | 50% | Assumption | |
Age at vaccination | 12Â years | Assumption | |
Booster vaccination | No booster vaccination in the base case analysis | Assumption | |